IMMUNOVANT, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 27.17 USD | -2.09% |
|
-3.72% | -35.51% |
| Apr. 20 | Immunovant Insider Sold Shares Worth $990,269, According to a Recent SEC Filing | MT |
| Apr. 20 | Immunovant Insider Sold Shares Worth $293,923, According to a Recent SEC Filing | MT |
Presentation Operator MessageOperator (Operator)Good morning. My name is Michelle, and I am yo...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Immunovant, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing treatments for patients with autoimmune diseases. Its product pipeline includes batoclimab (IMVT-1401), and IMVT-1402, both of which are novel, fully human monoclonal antibodies that target the neonatal fragment crystallizable receptor (FcRn). Batoclimab is a subcutaneous injection with dosing. Batoclimab is observed to reduce immunoglobulin G (IgG) antibodies that cause inflammation and disease. Its product candidate, batoclimab, is dosed in small volumes and with a 27-gauge needle. It is developing batoclimab for myasthenia gravis (MG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP) and Gravesâ disease (GD). IMVT-1402 is a fully human monoclonal antibody that inhibits FcRn. IMVT-1402 has also been observed in nonclinical studies to reduce IgG antibody levels. IMVT-1402 is delivered as a 2 mL simple subcutaneous injection.
Calendar
2024-06-30
- Q4 2024 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
27.17
USD
Average target price
50.43
USD
Spread / Average Target
+85.60%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -35.51% | 3.95B | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- IMVT Stock
- News Immunovant, Inc.
- Transcript : Immunovant, Inc. - Special Call
